Comprehensive Investigator's Brochure for Novel Immunotherapy
Development of a scientifically rigorous and regulatory-compliant IB that effectively communicated complex mechanism of action and safety profile for a first-in-class biologic.
Case Study Overview
EloquiMed created a scientifically robust Investigator's Brochure for a novel monoclonal antibody targeting immune dysregulation in autoimmune diseases, facilitating seamless progression through clinical development.
Client
Mid-size Biotechnology Company
Therapeutic Area
Immunology / Autoimmune Disorders
Document Type
Investigator's Brochure (IB)
Result
Successful IND/CTA approvals and accelerated Phase I-II timelines
The Challenge
Creating a comprehensive IB that accurately conveyed complex scientific mechanisms while addressing regulatory requirements for a first-in-human study.
Complex Mechanism of Action
Translating the intricate immunomodulatory mechanism targeting multiple cell signaling pathways into clear, scientifically accurate explanations accessible to investigators.
Novel Safety Profile
Characterizing potential safety concerns for a first-in-class biologic with a novel mechanism using limited preclinical data while adhering to regulatory expectations.
Accelerated Timeline
Developing a comprehensive IB under an aggressive 10-week timeline to support concurrent IND/CTA submissions in multiple regions.
Data Integration
Synthesizing fragmented datasets from multiple in vitro and in vivo models, integrating insights from similar mechanisms, and addressing data gaps with scientific rationale.
Key Documentation Challenges
Our Expert Solution
EloquiMed deployed a specialized team of immunology medical writers and regulatory experts to create a comprehensive IB that balanced scientific rigor with regulatory compliance.
Mechanism of Action Expert Panel
Convened a panel of immunology experts to develop clear mechanistic explanations supported by scientifically accurate figures and diagrams.
Integrated Nonclinical Assessment
Synthesized fragmented pharmacology, toxicology, and ADME data into a cohesive narrative with comprehensive tables and visual data representations.
Translational Safety Framework
Developed a structured risk assessment approach integrating target biology, animal model findings, and class effects to characterize the safety profile and guide clinical monitoring.
Multi-Regional Regulatory Strategy
Created a globalized IB structure meeting both FDA and EMA requirements while addressing region-specific aspects to enable concurrent IND/CTA submissions.
10
Week Timeframe
180+
Page Document
3
Regional Filings
Outcomes & Impact
Regulatory Success
All three IND/CTA submissions were accepted without information requests related to the IB, enabling a seamless transition to clinical development.
Accelerated Timeline
Clear safety characterization and monitoring guidelines enabled accelerated protocol development, reducing time to First-In-Human by approximately 3 months.
Scientific Excellence
The mechanistic explanations and visualizations were so effective they were repurposed for investor presentations and scientific publications.
"The IB developed by EloquiMed was exceptional in its scientific rigor and clarity. Complex immunology concepts were presented with remarkable clarity while maintaining scientific integrity. The document not only facilitated our regulatory submissions but became a foundational reference for our entire clinical program."
Key IB Features
Mechanistic Diagrams
Custom-created visual explanations of complex immune cell interactions and signaling pathways
Integrated Nonclinical Data
Comprehensive synthesis of pharmacology, toxicology, and ADME findings with expert interpretation
Risk Assessment Framework
Structured approach to potential risks with rationale for monitoring strategies
Clinical Guidance
Clear recommendations for dosing rationale, safety monitoring, and potential adverse event management
Development Process
Content Planning & Structure Development
Week 1-2
- Initial materials review and gap analysis
- Development of detailed IB structure and template
- Identification of key scientific messaging needs
- Planning of custom visual assets and tables
Core Content Development
Week 3-6
- Drafting of mechanism of action and pharmacology sections
- Development of integrated nonclinical summaries
- Creation of safety assessment and risk management framework
- Design and production of custom scientific illustrations
Expert Review & Refinement
Week 7-8
- Cross-functional review with client scientists and clinicians
- Regulatory expert review for compliance with global requirements
- Incorporation of feedback and document refinement
- Enhancement of critical sections based on expert input
Finalization & Submission Support
Week 9-10
- Final quality control and consistency checks
- Preparation of region-specific adaptations
- Support for inclusion in IND/CTA submissions
- Development of update plan for future IB versions
Related Case Studies
Need expert IB development?
Partner with EloquiMed for scientifically rigorous, reviewer-friendly Investigator's Brochures that advance your clinical development goals.